Premium
Homozygous 10q23/ PTEN deletion and its impact on outcome in glioblastoma: A prospective translational study on a uniformly treated cohort of adult patients
Author(s) -
Srividya Mallavarapu R.,
Thota Balaram,
Shailaja Bangalore C.,
Arivazhagan Arimappamagan,
Thennarasu Kandavel,
Chandramouli Bangalore A.,
Hegde Alangar S.,
Santosh Vani
Publication year - 2011
Publication title -
neuropathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 61
eISSN - 1440-1789
pISSN - 0919-6544
DOI - 10.1111/j.1440-1789.2010.01178.x
Subject(s) - pten , glioblastoma , medicine , prospective cohort study , oncology , cohort , cancer research , biology , genetics , pi3k/akt/mtor pathway , signal transduction
Tumors from a prospective cohort of adult patients with newly diagnosed glioblastoma ( n = 73), treated uniformly with radiochemotherapy, were examined for 10q23/ PTEN deletion by fluorescence in situ hybridization (FISH). Statistical methods were employed to evaluate the degree of association between 10q23/ PTEN deletion status and patient age. Survival analysis was performed using Kaplan‐Meier log‐rank test and multivariable Cox models to assess the prognostic value of 10q23/ PTEN deletion. Interestingly, 10q23/ PTEN homozygous deletion was frequent in patients >45 years of age ( P = 0.034) and the median age of patients harboring PTEN homozygous deletions was significantly higher than those with the retained status ( P = 0.019). 10q23/ PTEN homozygous deletion was associated with shorter survival in the entire cohort as well in patients >45 years ( P < 0.05 ), indicating that loss of 10q23/PTEN showed clinical importance in elderly patients. Our study highlights the independent prognostic/predictive value of 10q23/ PTEN deletion status as identified by FISH, particularly in glioblastoma patients aged >45 years.